Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Doramapimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 known ✓ | Q16539 | 10/20 | 1.00 |
| ▸ | TNF | P01375 | 7/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 3/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 3/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 3/20 | 1.00 |
| ▸ | DDR2 | Q16832 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | MUSK | O15146 | 1/20 | 1.00 |
| ▸ | MAP3K7 | O43318 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | CHEK2 | O96017 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | EGFR | P00533 | 1/20 | 1.00 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 1/20 | 1.00 |
| ▸ | HSPB1 | P04792 | 1/20 | 1.00 |
| ▸ | PRKCB | P05771 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Doramapimod SCHEMBL29353023 | 1.00 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| Doramapimod SCHEMBL10320344 | 0.99 | MAPK14 (0.98) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL20876996 | 0.96 | MAPK14 (0.93) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL14185084 | 0.95 | MAPK14 (0.91) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL6330722 | 0.95 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295302 | 0.95 | MAPK14 (1.00) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL5967533 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL13857350 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL295792 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 | |
| SCHEMBL29594033 | 0.94 | MAPK14 (0.89) | MAPK14TNFMAPK13MAPK12MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 650 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | Poolbeg Pharma (UK) Limited (GB) | 2024-11-19 | — | — | US | claimed |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION | 2023-09-14 | — | — | US | claimed |
| EP-3069732-B1 | DRUG FOR TREATING CORNEAL ENDOTHELIUM BY PROMOTING CELL PROLIFERATION OR INHIBITING CELL DAMAGE | THE DOSHISHA (JP) | 2023-07-12 | — | — | EP | claimed |
| WO-2023039578-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | OMEROS CORPORATION (US) | 2023-03-16 | — | — | WO | claimed |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | ORPH PHARMA IP COMPANY LIMITED (GB) | 2022-05-24 | — | — | US | claimed |
| US-11123349-B2 | Method of treatment | THE UNIVERSITY OF MELBOURNE (AU) | 2021-09-21 | — | — | US | claimed |
| EP-3111937-B1 | MEDICAMENT FOR TREATMENT OF LIVER CANCER | HELMHOLTZ ZENTRUM INFEKTIONSFORSCHUNG GMBH (DE) | 2020-06-17 | — | — | EP | claimed |
| EP-3632208-A1 | CELL STABILIZATION | Biomatrica, INC. (US) | 2020-04-08 | — | — | EP | claimed |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2018-03-15 | — | — | US | claimed |
| EP-3274053-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | The Brigham and Women's Hospital, Inc. (US) | 2018-01-31 | — | — | EP | claimed |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | claimed |
| US-6565880-B2 | Antiinflammatory agents | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-05-20 | — | — | US | claimed |
| US-20030091636-A1 | Methods for coating pharmaceutical core tablets | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| EP-1305050-A2 | IMPROVED ORAL DOSAGE FORMULATIONS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 2003-05-02 | — | — | EP | claimed |
| US-20030068340-A1 | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-04-10 | — | — | US | claimed |
| WO-2003015828-A1 | PARENTERAL FORMULATIONS OF 1-(5-TERT-BUTYL-2-P-TOLYL-2H-PRYRAZOL-3-YL)-3-[4-(2-MORPHOLIN-4-YL-ETHOXY)-NAPHTHALEN-1-YL]-UREA AND A CYCLODEXTRIN | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2003-02-27 | — | — | WO | claimed |
| US-20020031544-A1 | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl] urea | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2002-03-14 | — | — | US | claimed |
| WO-2002007772-A2 | IMPROVED ORAL DOSAGE FORMULATIONS | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) | 2002-01-31 | — | — | WO | claimed |
| US-6333325-B1 | ADMINISTERING PYRAZOLE DERIVATIVE OF UREA OR THIOUREA FOR THERAPY OF CYTOKINE MEDIATED DISEASE SUCH AS ACTUATE AND CHRONIC PAIN, CONTACT DERMATITIS, ATHEROSCLEROSIS, GLOMERULONEPHRITIS, REPERFUSION INJURY, BONE RESORPTION | BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-12-25 | — | — | US | claimed |
| US-6319921-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, MULTIPLE SCLEROSIS, GUILLAIN-BARRE SYNDROME, CROHN'S DISEASE ULCERATIVE COLITIS, PSORIASIS, GRAFT VERSUS HOST DISEASE, SYSTEMIC LUPUS ERYTHEMATOSUS AND DIABETES | BOERHINGER INGELHEIM PHARMACEUTICALS, INC. | 2001-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030091636-A1 | Methods for coating pharmaceutical core tablets | CCT4, CCT2, NOD2 | MAPK14 1638/4885TNF 894/4885MAPK13 2112/4885 |
| US-12145981-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, CCL11 | MAPK14 14/4885TNF 67/4885MAPK13 23/4885 |
| US-11123349-B2 | Method of treatment | TNF, IL1B, IL1A | MAPK14 3859/4885TNF 1/4885MAPK13 3789/4885 |
| US-20230285556-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | TP53, CD4, MCL1 | MAPK14 4032/4885TNF 3356/4885MAPK13 4273/4885 |
| US-20030068340-A1 | Parenteral formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea | IL2, TTR, THPO | MAPK14 1267/4885TNF 181/4885MAPK13 745/4885 |
| US-20020031544-A1 | Oral dosage formulations of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl] urea | CCT4, NOD2, CCT2 | MAPK14 1207/4885TNF 1571/4885MAPK13 1657/4885 |
| US-20030130309-A1 | Methods of treating cytokine mediated diseases | IL2, IFNG, IL1A | MAPK14 3143/4885TNF 18/4885MAPK13 3752/4885 |
| US-20180071376-A1 | TOLEROGENIC NANOPARTICLES FOR TREATING DIABETES MELLITUS | IAPP, NFATC1, CD4 | MAPK14 2820/4885TNF 299/4885MAPK13 1694/4885 |
| US-11339207-B2 | Methods and compounds for the treatment or prevention of severe influenza | CXCL10, MAPK10, MAPK1 | MAPK14 15/4885TNF 64/4885MAPK13 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.